X
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): AMT-260
Therapeutic Area: Neurology Product Name: AMT-260
Highest Development Status: Preclinical Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Uniqure
Deal Size: $106.2 million Upfront Cash: $54.6 million
Deal Type: Acquisition June 22, 2021
Details:
Under the license and collaboration agreement, REGENXBIO received equity in Corlieve and is eligible to receive milestone payments and royalties on net sales of AMT-260.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Recombinant human homeoprotein Engrailed 1
Therapeutic Area: Neurology Product Name: BREN-02
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 23, 2020
Details:
U.S. FDA has granted orphan drug designation to BrainEver's product BREN-02, the recombinant human homeoprotein Engrailed 1, for the treatment of amyotrophic lateral sclerosis.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Ezeprogind
Therapeutic Area: Neurology Product Name: AZP2006
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 23, 2020
Details:
The patent complements the portfolio of patents covering Ezéprogind and its therapeutic uses already granted in Europe, and in 11 other countries including Japan and China.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
